[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:gain-of-chromosome-18q":3},{"name":4,"total":5,"recruiting":6,"trials":7},"Gain of Chromosome 18q",2,1,[8,16],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06100237","Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)",[12],"Phase 2","RECRUITING","2026-08-26T02:16:24.135291Z","2026-05-05T02:43:29.197990Z",{"nct_id":17,"title":18,"phases":19,"status":20,"updated_at":21,"content_modified":22},"NCT07029776","MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma",[12],"NOT_YET_RECRUITING","2026-08-26T02:18:08.005333Z","2026-05-05T02:43:28.128103Z"]